Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

crizotinib

- PMLiVE

Roche’s Tecentriq misses survival mark in frontline NSCLC

Keytruda proving hard to beat

- PMLiVE

Labour party divided on Brexit ‘People’s Vote’

Growing support for second referendum being resisted by party leaders

- PMLiVE

Pfizer’s Prevnar-13 successor takes aim at Merck rival

Rivals look to broaden coverage across strains

Roche Basel Switzerland

Dismay as NICE rejects Roche’s MS drug Ocrevus

Treatment deemed too costly to treat primary progressive MS

- PMLiVE

MSD wins key EU approval for Keytruda, Alimta combo

Decision keeps Keytruda well ahead of rival Tecentriq

- PMLiVE

FDA gives Loxo breakthrough tag for second cancer drug

US regulatory body to expect a NDA for LOXO-292 in late 2019

Sanofi reception

Sanofi gets EU OK for Ablynx flagship drug Cablivi

EMA clears the drug to treat adults with aTTP

- PMLiVE

Alnylam gets EU nod for Onpattro amid pricing backlash

However the drug’s price could be lowered in the EU due to direct competition

- PMLiVE

Pfizer abandons antibody for Duchenne

Latest to fail in myostatin inhibitor class

- PMLiVE

Roche highlights Hemlibra data as key FDA date approaches

Expanded use would see revenues take off

Roche Basel Switzerland

Affimed rockets on $5bn-plus Roche immuno-oncology deal

Deal is latest in series of big pharma investments in cancer immunotherapies

- PMLiVE

Roche Diagnostics’ chief heads for the exit

No surprise if Diggelmann resurfaces at diagnostics start-up or rival

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links